Therapeutic angiogenesis induced by controlled release of fibroblast growth factor-2 from injectable chitosan/non-anticoagulant heparin hydrogel in a rat hindlimb ischemia model

Wound Repair and Regeneration

Volumn 15, Issue 1, 2007, Pages 58-65

  Fujita, Masanori ^a   Ishihara, Masayuki ^a   Shimizu, Masafumi ^a   Obara, Kiyohaya ^a   Nakamura, Shingo ^a   Kanatani, Yasuhiro ^a   Morimoto, Yuji ^a   Takase, Bonpei ^a   Matsui, Takemi ^a   Kikuchi, Makoto ^a   Maehara, Tadaaki ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; FIBROBLAST GROWTH FACTOR 2; HEPARIN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GASTROCNEMIUS MUSCLE; HYDROGEL; LIMB BLOOD FLOW; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; RAT; THIGH; VASCULARIZATION; WOUND HEALING IMPAIRMENT;

ANIMALS; BIOCOMPATIBLE MATERIALS; CHITOSAN; COLLATERAL CIRCULATION; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HINDLIMB; HYDROGEL; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33846419133     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2006.00185.x     Document Type: Article

References (40)

1. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. Therapeutic interventions for enhancing collateral development by administration of growth factor: basic principles, early results and potential hazards. Cardiovasc Res 2001; 49: 532-42.
2. Baffour R, Garb JL, Kaufman J, Berman J, Rhee SW, Norris MA, Friedmann P. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J Surg Res 2000; 93: 219-29.
3. Tabata Y, Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 1999; 20: 2169-75.
4. Gospodarowicz D. Fibroblast growth factor and its involvement in developmental processes. Curr Topics Dev Biol 1990; 24: 57-93.
5. Slack JM, Darlington BG, Heath JK, Godsave SF. Mesoderm induction in early Xenopus embryos by heparin binding growth factors. Nature 1987; 326: 197-200.
6. Abraham JA, Mergia J, Whang L, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz D, Fiddes JC. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986; 233: 545-8.
7. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmcol Sci 2001; 22: 201-7.
8. Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 1988; 81: 1572-7.
9. Nakajima F, Ogasawara A, Goto K, Moriya H, Ninomiya Y, Einhorn TA, Yamazaki M. Spatial and temporal gene expression in chondrogenesis during fracture healing and the effects of basic fibroblast growth factor. J Orthop Res 2001; 19: 935-44.
10. Tsuboi R, Rifkin DB. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impairing db/db mices. J Exp Med 1990; 172: 245-51.
11. Graham A. The use of growth factors in clinical practice. J Wound Care 1998; 7: 536-40.
12. Obara K, Ishihara M, Ishizuka T, Fujita M, Ozeki Y, Maehara T, Saito Y, Yura H, Matsui T, Hattori H, Kikuchi M, Kurita A. Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice. Biomaterials 2003; 24: 3437-44.
13. Ishihara M, Ono K. Structure and function of heparin and heparan sulfate: heparinoid library and modification of FGF-activities. Trends Glycosci Glycotech 1998; 10: 223-33.
14. Ishihara M. Biosynthesis, structure, and biological activity of basic FGF binding domains of heparan sulfate. Trends Glycosci Glycotech 1993; 5: 343-54.
15. Salmivirta M, Lidhold K, Lindahl U. Heparan sulfate: a piece of information. FASEB J 1996; 10: 1270-9.
16. Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anti-coagulation. Thromb Res 1994; 75: 1-32.
17. Yayon A, Klabsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841-8.
18. Rapraeger AC, Krufla A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 240-7.
19. Ishihara M, Sato M, Hattori H, Saito Y, Yura H, Ono K, Masuoka K, Kikuchi M, Fujikawa K, Kurita A. Heparin-carrying polystyrene (HCPS)-bound collagen substratum to immobilize heparin-binding growth factors and to enhance cellular growth. J Biomed Mater Res 2001; 56: 536-44.
20. Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. J Biomed Mater Res 2001; 56: 216-21.
21. Ishihara M, Obara K, Ishizuka T, Fujita M, Sato M, Masuoka K, Saito Y, Yura H, Matsui T, Hattori H, Kikuchi M, Kurita A. Controlled release of fibroblast growth factors and heparin from photocrosslinked chitosan hydrogels and subsequent effect on in vivo vascularization. J Biomed Mater Res 2003; 64A: 551-9.
22. Ono K, Saito Y, Yura H, Ishikawa K, Kurita A, Akaike T, Ishihara M. Photocrosslinkable chitosan as a biological adhesive. J Biomed Mater Res 2000; 49: 289-95.
23. Ono K, Ishihara M, Ozeki Y, Deguchi H, Sato M, Saito Y, Yura H, Sato M, Kikuchi M, Kurita A, Maehara T. Experimental evaluation of photocrosslinkable chitosan as a biological adhesive with surgical application. Surgery 2001; 130: 844-50.
24. Ishihara M, Nakanishi K, Ono K, Sato M, Kikuchi M, Saito Y, Yura H, Matsui T, Hattori H, Uenoyama M, Kurita A. Photocrosslinkable chitosan as a dressing for wound occlusion and accerelator in healing process. Biomaterials 2002; 23: 833-40.
25. Ishihara M, Ono K, Ishikawa K, Hattori H, Saito Y, Yura H, Akaike T, Ozeki Y, Tanaka S, Mochizuki H, Kurita A. Enhanced ability of heparin-carrying polystyrene (HCPS) to bind to heparin-binding growth factors and inhibit growth factor-induced endothelial cell growth. J Biochem 2000; 127: 797-803.
26. Ono K, Ishihara M, Ishikawa K, Ozeki Y, Deguchi H, Sato M, Hashimoto H, Saito Y, Yura H, Kurita A, Maehara T. Periodate-treated, non-anticoagulant heparin carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumor growth and metastasis to the lung. Br J Cancer 2002; 86: 1803-12.
27. Fujita M, Ishihara M, Ono K, Matsumura K, Saito Y, Yura H, Morimoto Y, Shimizu M, Takase B, Ozaki S, Kikuchi M Maehara T. Inhibition of neointimal proliferation in balloon-injured arteries by periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS). J Cardiovasc Pharmacol 2004; 43: 31-8.
28. Fujita M, Ishihara M, Shimizu M, Obara K, Ishizuka T, Saito Y, Yura H, Morimoto Y, Takase B, Matsui T, Kikuchi M, Maehara T. Vascularization in vivo caused by the controlled release of fibroblast growth factor-2 from an injectable chitosan/non-anticoagulant heparin hydrogel. Biomaterials 2004; 25: 699-706.
29. Ikenaga S, Hamano K, Nishida M, Kobayashi T, Li TS, Kobayashi S, Matsuzaki M, Zempo N, Esato K. Autologous bone marrow implantation induced angiogenesis and improved deteriorated exercise capacity in a rat ischemic hindlimb model. J Surg Res 2001; 96: 277-83.
30. Takeshita S, Isshiki T, Mori H, Tanaka E, Eto K, Miyazawa Y, Tanaka A, Shinozaki Y, Hyodo K, Ando M, Kubota M, Tanioka K, Umetani K, Ochiai M, Sato T, Miyashita H. Use of synchrotron radiation microangiography to assess development of small collateral arteries in a rat model of hindlimb ischemia. Circulation 1997; 95: 805-8.
31. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16: 181-91.
32. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest 1994; 93: 662-70.
33. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995; 21: 314-24.
34. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, Taiji M, Noguchi H, Takeshita S, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999; 33: 1397-84.
35. Kobayashi T, Hamano K, Li TS, Katoh T, Kobayashi S, Matsuzaki M, Esato K. Enhancement of angiogenesis by the implantation of self bone marrow cells in a rat ischemic heart model. J Surg Res 2000; 89: 189-95.
36. Hamano K, Li TS, Kobayashi T, Kobayashi S, Matsuzaki M, Esato K. Angiogenesis induced by the implantation of self-bone marrow cells: a new material for therapeutic angiogenesis. Cell Transplant 2000; 9: 439-43.
37. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23.
38. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, Rosenfield K, Weir L, Brogi E, Jurayj D. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 1996; 7: 959-88.
39. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M, Sugimachi K, Sueishi K. Angiogenic gene therapy for experimental critical limb ishemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90: 966-73.
40. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model. Circulation 2001; 104: 2344-50.